Clinical trials: Statin Dose
Coronary Artery
Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery
Trimetazidine is a metabolic agent without any negative inotropic or vasodilatory properties. In addition, previous reports showed that trimetazidine was effective in reducing intracoronary platelet aggregation and preventing…
- Trial name
- NCT01857921
- Testing
- Pravastatin 20mg/day for 12 months after randomization, Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Yonsei University
Dyslipidemia, Hypercholesterolemia
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.
- Conditions
- Dyslipidemia, Hypercholesterolemia, High Cholesterol
- Trial name
- NCT05421078
- Testing
- Obicetrapib
- Where
- 10 sites in Japan
- Volunteers
- 102 people
- Sponsor
- NewAmsterdam Pharma
Hypercholesterolemia, Diabetes
Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?
We aimed to address the issue whether statins affect insulin resistance. To this end, we combined the available state-of-the art technology for detailed assessment of both whole-body and tissue specific insulin sensitivity in…
- Conditions
- Hypercholesterolemia, Diabetes, Cardiovascular Disease
- Trial name
- NCT00704314
- Testing
- Simvastatin
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Acute Coronary Syndrome
Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)
The aim of the project is to compare the nephro-protective effects of high-dose atorvastatin and high-dose rosuvastatin on the incidence of Contrast Induced-Acute Kidney Injury in patients with non-ST-elevation acute coronary…
- Trial name
- PRATO-ACS-2 (NCT01870804)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- Italy
- Volunteers
- 760 people
- Sponsor
- Centro Cardiopatici Toscani
Hypercholesterolemia
Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
The purpose of this study is to compare the efficacy of a Vytorin 10/80 tablet, an approved agent for the treatment of elevated LDL cholesterol which combines the cholesterol absorption inhibitor Ezetimibe 10 mg and simvastatin…
- Trial name
- NCT00762164
- Testing
- Vytorin, Simvastatin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Bronx VA Medical Center
Atherosclerosis, Thromboembolism
Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus
The purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE).
- Conditions
- Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus
- Trial name
- NCT00371501
- Testing
- Rosuvastatin, aspirin
- Where
- Hong Kong
- Volunteers
- 72 people
- Sponsor
- Tuen Mun Hospital
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol…
- Trial name
- GAUSS-2 (NCT01763905)
- Testing
- Evolocumab, Ezetimibe
- Where
- 58 sites in United States, Australia and 12 more
- Volunteers
- 307 people
- Sponsor
- Amgen
Hypercholesterolemia
Dose-escalating Safety Study in Subjects on Stable Statin Therapy
The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.
- Trial name
- NCT00231569
- Where
- 5 sites in United States, Netherlands
- Volunteers
- 74 people
- Sponsor
- Kastle Therapeutics, LLC
Dyslipidemia, Coronary Artery Disease
Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
This study is designed to characterize the pharmacokinetics of multi-dose RVX000222 and atorvastatin and rosuvastatin when either statin is administered in combination with RVX000222 in subjects with dyslipidemia.
- Trial name
- NCT01863225
- Testing
- RVX000222, Rosuvastatin, Atorvastatin
- Where
- Australia
- Volunteers
- 13 people
- Sponsor
- Resverlogix Corp
Statin Dose
Effective Dose of Statin Post PCI
In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded
- Trial name
- NCT04923152
- Testing
- moderate statin dose, high dose statin
- Where
- Iran
- Volunteers
- 582 people
- Sponsor
- Shiraz University of Medical Sciences
Coronary Artery Disease, Dyslipidemias
Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)
the investigators would like to compare the differences between roschvastin and atovastatin in patients who require high-dose statin/ejetimib to undergo a new generation of drug elution stent implantation for cardiovascular…
- Trial name
- NCT05910476
- Testing
- a high dose of statin/ezetimib
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Dyslipidemia
The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)
This study will investigate the effect of MK0859 on lipoprotein metabolism in patients with dyslipidemia already on statin therapy.
- Trial name
- NCT00990808
- Testing
- anacetrapib, Comparator: atorvastatin
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Disorder; Heart, Functional, Postoperative, Cardiac Surgery, Cardiac Insufficiency Following Cardiac Surgery
Statin Therapy In Atrial Refractoriness and Reperfusion Injury
Patients with coronary artery disease are often prescribed drugs called statins because research has shown that, by lowering cholesterol, they reduce the risk of having a heart attack or other complications in the long-term.
- Conditions
- Disorder; Heart, Functional, Postoperative, Cardiac Surgery, Cardiac Insufficiency Following Cardiac Surgery, Atrial Fibrillation, Ischaemia-reperfusion Injury
- Trial name
- STARR (NCT01780740)
- Testing
- Atorvastatin
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Oxford
Hypercholesterolemia
Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)
A group of ~ 225 patients were switched from atorvastatin to an equivalent statin either by their physicians usual management or by an collaborative pharmacist coordinated process.
- Trial name
- NCT01222182
- Testing
- atorvastatin
- Where
- United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Healthy
Pharmacodynamic Drug Interaction Between Cilostazol and Statins
The purpose of this study is to evaluate pharmacodynamic drug interaction between cilostazol and statins (simvastatin as a CYP3A substrate and rosuvastatin as a non-CYP3A substrate) in healthy male subjects.
- Trial name
- SMCCPT-100 (NCT01870466)
- Testing
- Cilostazol, Simvastatin, Rosuvastatin
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Atherosclerosis
Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins
To obtain safety and tolerability information in healthy subjects is administered as a single dose
- Trial name
- NCT01587365
- Testing
- BMS-962476
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hypercholesterolemia, Mixed Dyslipidemia
SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®
In this study, a survey of office-based cardiologists and lipid management specialists will be conducted on treatment decisions for NUSTENDI® (bempedoic acid 180 mg fixed dose combination [FDC] with ezetimibe 10 mg) followed by a…
- Trial name
- NCT05546398
- Testing
- Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab, No study drug
- Where
- 63 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
The purpose of this study is to determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
- Trial name
- NCT00966472
- Testing
- Erlotinib + Rosuvastatin
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Ottawa Hospital Research Institute
Medication Adherence
Reducing African-American CVD Disparities Intervention Optimization (RADIO) Individuals on Statins
The purpose of this project is to identify the minimum effective dose (MED) of a multi-component behavioral change intervention required to increase levels of medication adherence among Black and African American individuals on…
- Trial name
- RADIO (NCT05954000)
- Testing
- 5 Behavioral Change Techniques
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Northwell Health
A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB.
Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study
Periprocedural treatment with high-dose statins is known to have cardioprotective and pleiotropic effects, such as anti-thrombotic and anti-inflammatory actions.
- Trial name
- NCT01971606
- Testing
- Rosuvastatin
- Where
- South Korea
- Volunteers
- 234 people
- Sponsor
- Yonsei University